Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Clonal heterogeneity has not been described in patients with myelodysplastic syndrome with isolated del(5q), for which lenalidomide has emerged as a highly potent treatment. However, transformation to acute myeloid leukemia is occasionally observed, particularly in patients without a cytogenetic res...

Full description

Bibliographic Details
Main Authors:	Jädersten, M, Saft, L, Pellagatti, A, Göhring, G, Wainscoat, J, Boultwood, J, Porwit, A, Schlegelberger, B, Hellström-Lindberg, E
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
by: Jadersten, M, et al.
Published: (2005)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
by: Pellagatti, A, et al.
Published: (2006)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
by: Scharenberg, C, et al.
Published: (2011)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
by: Pellagatti, A, et al.
Published: (2007)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
by: Boultwood, J, et al.
Published: (2012)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
by: Caceres, G, et al.
Published: (2013)

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES
by: Ballabio, E, et al.
Published: (2010)

Clonality in the myelodysplastic syndromes.
by: Boultwood, J, et al.
Published: (2001)

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.
by: Pellagatti, A, et al.
Published: (2010)

5q- syndrome.
by: Boultwood, J, et al.
Published: (2012)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
by: Pellagatti, A, et al.
Published: (2011)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
by: Pellagatti, A, et al.
Published: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
by: Pellagatti, A, et al.
Published: (2011)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
by: Boultwood, J, et al.
Published: (2007)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
by: Pellagatti, A, et al.
Published: (2009)

Progression in patients with low- and intermediate1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
by: Scharenberg, C, et al.
Published: (2016)

Advances in the 5q- syndrome.
by: Boultwood, J, et al.
Published: (2010)

Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts
by: Malcovati, L, et al.
Published: (2010)

Strong economic fundamentals prevail
by: Zainal Abidin, Irwan Shah
Published: (2016)

Constraints ahead but optimism prevails

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
by: Fidler, C, et al.
Published: (2004)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
by: Nikpour, M, et al.
Published: (2007)

Indonesia's next president : will Jokowi prevail
by: Bilveer Singh
Published: (2014)

The 5q-syndrome.
by: Boultwood, J, et al.
Published: (1994)

The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome.
by: Boultwood, J
Published: (2011)

Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients
by: Gooding, S, et al.
Published: (2021)

The Shia-Sunni divide : tunnel vision prevails
by: Dorsey, James M.
Published: (2013)

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
by: Boultwood, J, et al.
Published: (2013)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2010)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
by: Pellagatti, A, et al.
Published: (2009)

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
by: Jan, Max, et al.
Published: (2021)

Persistent malignant stem cells in del(5q) myelodysplasia in remission.
by: Tehranchi, R, et al.
Published: (2010)

Cortical and clonal contribution of tbr2 expressing progenitors in the developing mouse brain.
by: Vasistha, N, et al.
Published: (2015)

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
by: Lee, HC, et al.
Published: (2024)

Modelling of prevailing water distribution network in Putrajaya, Malaysia
by: Mohamad, Nur Diyana, et al.
Published: (2019)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
by: Pellagatti, A, et al.
Published: (2010)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
by: Follo, M, et al.
Published: (2019)

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
by: Dorans, Kimberly, et al.
Published: (2017)

The 5q- syndrome.
by: Giagounidis, A, et al.
Published: (2004)

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34+ progenitor cells
by: Davies, C, et al.
Published: (2013)